Neoadjuvant and definitive chemotherapy or chemoradiation for stage III and IV vulvar cancer: A pooled Reanalysis.

Autor: Forner DM; Evangelisches Krankenhaus Köln Kalk, Buchforststrasse 2, D-51103 Köln, Germany. Electronic address: dr.forner@gmx.de., Mallmann P; Universitäts-Frauenklinik Köln, Kerpener Str. 34, D-50931 Köln, Germany.
Jazyk: angličtina
Zdroj: European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2017 May; Vol. 212, pp. 115-118. Date of Electronic Publication: 2017 Mar 19.
DOI: 10.1016/j.ejogrb.2017.03.030
Abstrakt: Objectives and Methods: A number of publications study the treatment of advanced vulvar cancer by neoadjuvant or definitive chemotherapy (CT) or chemoradiation (CRT); however, the reported survival rates vary widely. In a pooled reanalysis of the published data, we studied the factors influencing patients' survival.
Results: We included 97 patients with stage III and IV vulvar cancer of publications in our study. In the pooled reanalysis we found that neoadjuvant therapy plus surgery lead to significantly better 5YSR (73%) than definitive CRT (43%) alone. No significant difference was found between CRT (5YSR: 69%) and CT (77%, p=0.11) in the neoadjuvant setting. In addition, patients showing a positive response to CT or CRT had a better 5YSR (67% vs. 20%, p=0.001).
Conclusion: Neoadjuvant therapy plus surgery can improve survival of patients with advanced vulvar cancer.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: